Piroheptine
Piroheptine is a muscarinic acetylcholine receptor (mAChR) antagonist and dopamine reuptake inhibitor. Piroheptine blocks the high-affinity dopamine transport system, prevents MPP+ uptake into dopaminergic neurons, and exerts anticholinergic activity. Piroheptine completely prevents MPTP (HY-W114750)-induced loss of striatal dopamine and DOPAC, and increases striatal dopamine levels. Piroheptine can be used in studies related to Parkinson's disease.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 16378-21-5
- Formel: C22H25N
- Molecular Weight:303.45
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 8-week-old, 20-30 g, Parkinsonism induced via 4 intraperitoneal injections of 10 mg/kg MPTP at 1-hour intervals)[1]
-
Dosage:20 mg/kg
-
Administration:i.p.; 30 minutes before each of 4 MPTP injections (1 hour apart); single treatment (piroheptine-alone group)
-
Result:Completely prevented MPTP-induced striatal dopamine loss, resulting in levels of 9.5 μg/g wet tissue.
Completely prevented MPTP-induced striatal DOPAC loss, resulting in levels of 0.8 μg/g wet tissue.
Increased striatal dopamine content to 10.2 μg/g wet tissue (approximately 10% higher than saline controls) when administered alone.
Chemical Information
-
CAS. Nr. 16378-21-5
-
Molecular Weight 303.45
-
Formel C22H25N
-
SMILES
C=1C=CC2=C(C1)C(C=3C=CC=CC3CC2)=C4CCN(CC)C4C
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Piroheptine Related Classifications
HY-W683866 Related Classifications
Powered by Bioz